Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GFH375 in Patients With KRAS G12D Mutant Advanced Solid Tumors

NCT06500676 is registered in ClinicalTrials.gov with Genfleet Therapeutics (Shanghai) Inc. as lead sponsor.

NCT NCT06500676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06500676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GFH375 in Patients With KRAS G12D Mutant Advanced Solid Tumors
Lead sponsor
Genfleet Therapeutics (Shanghai) Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 9, 2024
Completion date
December 31, 2028
Enrollment
407 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, kras g12d mutations